Merck & Co. Inc. stock (US58933Y1055): oncology strength after Q1 earnings and Keytruda momentum

Merck & Co. Inc. has reported higher Q1 2026 sales driven by blockbuster cancer drug Keytruda and vaccines, while reaffirming its full?year guidance. How does the pharma heavyweight generate its revenue – and what matters now for US investors?

Merck & Co. Inc. has started 2026 on a solid footing, posting higher first-quarter revenue on the back of continued demand for cancer therapy Keytruda and its vaccines portfolio, while reiterating its full-year outlook, according to a company release published on 04/25/2026.Merck press release as of 04/25/2026

In addition, the New Jersey–based pharmaceutical group highlighted further regulatory progress for Keytruda in solid tumors and reported steady contributions from its animal health business, underscoring the diversified nature of its revenue base, as reported by financial media coverage on the same day.Reuters as of 04/25/2026

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, biotechnology, healthcare
• Headquarters/country: Kenilworth, New Jersey, United States
• Core markets: Global prescription drugs, vaccines, animal health
• Key revenue drivers: Oncology therapies (Keytruda), vaccines, hospital acute care medicines, animal health products
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co. Inc.: core business model

Merck & Co. Inc. is a global research-driven pharmaceutical company focused on prescription medicines, vaccines and animal health products. The group’s business model centers on discovering, developing, manufacturing and marketing innovative therapies that address significant unmet medical needs in oncology, infectious diseases, cardiometabolic conditions and other serious illnesses.

A substantial share of Merck’s revenue comes from branded human health products that are protected by patents, enabling premium pricing in key markets such as the United States, Europe and parts of Asia. The company invests heavily in research and development to refresh its product portfolio and extend the lifecycle of existing franchises, with oncology and vaccines representing strategic focus areas.

Beyond proprietary medicines, Merck also generates income from alliances, licensing arrangements and collaboration agreements with other pharmaceutical and biotechnology companies. These partnerships can involve co-development of drug candidates, shared commercialization responsibilities or royalties on sales, providing additional revenue streams while spreading development risks.

Main revenue and product drivers for Merck & Co. Inc.

The single most important product for Merck at present is cancer immunotherapy Keytruda, which is approved in multiple indications, including non-small cell lung cancer, melanoma and several other solid tumors. In the first quarter of 2026, Keytruda revenue continued to grow year-on-year, helped by expanded usage across earlier lines of therapy and broader geographic adoption, according to the company’s earnings announcement.Merck press release as of 04/25/2026

Vaccines remain a second major pillar for Merck, with products such as its human papillomavirus vaccine Gardasil contributing meaningfully to sales. Demand for vaccines tends to be influenced by public immunization programs, private insurance coverage and evolving disease awareness, making this segment relatively resilient but still sensitive to policy changes.

In addition, Merck operates an animal health division that supplies pharmaceuticals and vaccines for livestock and companion animals. While smaller than the human health unit, animal health offers a diversified revenue base tied to global protein consumption and pet care trends. This business can help offset some volatility in prescription drug sales, particularly when individual human medicines face patent expiration.

Homepage and official information

For investors and observers seeking direct access to primary company information, Merck maintains a detailed corporate website with sections on products, research pipelines and sustainability initiatives. The site also contains press releases, financial reports and updates on clinical trial milestones that can provide further context on the group’s strategic direction.

The investor-specific portion of the website usually offers quarterly and annual filings, presentations and webcasts that explain recent performance, capital allocation decisions and research priorities. These materials are particularly useful for US investors following the stock on the New York Stock Exchange, where Merck is a large component of key healthcare indices and often features in diversified equity portfolios.

Why Merck & Co. Inc. matters for US investors

Merck is one of the largest healthcare companies in the United States by market capitalization and plays a significant role in major stock benchmarks that many US investors track. Its performance can influence healthcare sector indices and broad-based funds, meaning developments at the company may indirectly affect diversified portfolios that include the NYSE-listed stock.

The company’s exposure to US drug pricing, regulatory decisions from the Food and Drug Administration and reimbursement trends from public and private insurers means that domestic healthcare policy remains a key factor. For US investors, Merck’s ability to navigate potential pricing pressure while sustaining investment in research and development is an important consideration when assessing the stability of its earnings base.

At the same time, Merck’s international footprint, particularly in oncology and vaccines, provides revenue diversification beyond the US market. This global reach can help cushion localized policy changes while offering upside from expanding access to cancer care and immunization in emerging economies, although it also introduces currency and geopolitical risks that investors should keep in mind.

Conclusion

Merck & Co. Inc. entered 2026 with ongoing momentum in oncology and vaccines, as reflected in its first-quarter results and maintained full-year guidance. The company’s strong dependence on Keytruda highlights both the power of a successful flagship product and the importance of continued pipeline development to prepare for future patent expirations. With a diversified portfolio that includes animal health and a broad international presence, Merck remains a key name in the global pharmaceutical landscape and a notable component of US healthcare exposure, while developments in regulation, pricing and clinical data will remain central factors for observers monitoring the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.